GLP-1 agonists containing semaglutides such as Ozempic, Wegovy, Munjaro and Zepbound, were originally intended to treat type 2 diabetes and obesity.
However, in recent months, research has shown these Popular medicines It can have many other health benefits.
Some have argued that GLP-1 could ultimately become a new “all drug.”
Risk of diabetes combined with Mediterranean diet and other lifestyle changes
Dr. Angela Fitch, co-founder and chief medical officer of Candewell, a Boston-based “weight-inclusive” healthcare company, said he would be careful about labeling drugs as “all drugs,” but agrees that GLP-1 has shown a promise.
“GLP-1 is currently approved Treatment of obesitytype 2 diabetes, secondary prevention of cardiovascular disease, metabolism-related fatty liver disease, chronic kidney disease of diabetic patients and sleep apnea,” she told Fox News Digital.
“More research is needed to determine its effectiveness in treating other chronic diseases.”
However, drugs have shown “notable promises” in areas such as addiction treatment and improved neurological conditions. Like Alzheimer’ssaid Fitch.
DNA testing reveals which children are at higher risk of obesity in adulthood
“They’re going to be low blood pressurelowers cholesterol and reduces visceral steatosis,” she said. They have many clinical signs today, but there are even more clinical signs. ”
Fitch has listed the following major benefits of GLP-1 drugs:
Dr. Brett Osborne, a Florida neurosurgeon and longevity expert, believes the GLP-1 will “stay here.”
“These drugs don’t just treat obesity, they already show everything from cardiovascular disease to neurodegenerative diseases. Being addicted“He told Fox News Digital.
“I said this before, but again, these are not amenities. They are the holy grail of modern medicine.”
The most common side effects of GLP-1 drugs are Gastrointestinal related.
According to Fitch, this includes nausea, vomiting, diarrhea, constipation and bloating, especially during the initial dose escalation period.
“These symptoms It often improves over time, but for some patients it can be limited,” she said.
Other, more serious, rare, risks include pancreatitis, gallbladder disease, and potential renal damage. Experts warned that severe dehydration was caused, especially when vomiting caused them.
Dr. Marc Siegel, senior medical analyst at Fox News, has previously warned about side effects of GLP-1.
“Not everyone tolerate them well and we still don’t have a complete handle on long-term side effects,” he told Fox News Digital at the time.
“I certainly think they are useful — and you can think of many situations where they reduce the risk of Heart diseasestroke, diabetes, cancer, and the need for bariatric surgery — but they certainly aren’t perfect for one size, and most are not first-line therapy either. ”
Not all GLP-1 receptor agonists are the same, Fitch warned.
“They all act on the same basic pathway, but their effectiveness, side effects profile and cardiovascular benefits can vary significantly,” she told Fox News Digital.
Semaglutides such as Ozempic and Wegovy are currently considered to be the most powerful GLP-1 in both Weight loss Glycemic controls stated with evidence of cardiovascular benefits in people with type 2 diabetes and obese.
Semaglutide has also been approved as a treatment for mash (metabolic dysfunction-associated steatohepatitis, severe fatty liver disease).
“Tilzepatide (Moonjaro, Zepbound) is a dual GIP/GLP-1 agonist and shows even greater weight loss in the trial with a similar side-effect profile,” Fitch said.
“Tilzepatide is approved for sleep apnea and is undergoing clinical trials for other indications.”
Based on himself Clinical experienceOsborne repeated that tilzepatide is often a “good drug.”
“This means that it’s a dual incretin and targeting two biochemical pathways,” he told Fox News Digital. “So, not surprising, for patients who plateau with Wegovy, zepbound often jumps weight loss.”
The GLP-1 is not a “magic bullet,” Fitch points out, and its diet, exercise, sleep and sleep. Changes in behavior It is still essential to enjoying the full benefits.
“Before taking GLP-1, people need to know that side effects are common and consistent clinical care and surveillance is required to ensure safety and efficacy,” she advised.
Click here to sign up for our health newsletter
“It’s not something that people should access through forms on the internet and treat themselves without good, comprehensive, longitudinal care.”
In chronic conditions such as obesity Type 2 diabetesFitch recommends long-term or indefinite use as the best approach.
“This approach is still under investigation, but lowering the dose can be a viable maintenance strategy once a healthy weight reaches it,” she said.
“Patients should consult with their physician to determine which course of action is best for their specific needs.”
Visit us for more health articles www.foxnews.com/health
Anyone interested in starting GLP-1 drugs should Please consult a doctor Discuss potential benefits and risks.
